{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:52:18Z","timestamp":1782960738712,"version":"3.54.5"},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Anim Models and Exp Med"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>China is a high\u2010burden country for multidrug\u2010resistant tuberculosis\/rifampin\u2010resistant tuberculosis (MDR\/RR\u2010TB). Fluoroquinolones (FQs) are key drugs for the treatment of patients with MDR\/RR\u2010TB. However, research on the resistance of FQs in Beijing is limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We collected clinical isolates from all patients with pulmonary TB in Beijing from January 2016 to December 2021, conducted drug\u2010sensitivity tests and sequencing for levofloxacin (LFX) and moxifloxacin (MFX), and collected the treatment plans and outcomes of the patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 8512 clinical isolates were collected from patients with pulmonary TB, and 261 RR\u2010TB strains were screened. The proportions of drug\u2010sensitive and drug\u2010resistant strains significantly differed by age group and treatment history. The rates of LFX and MFX resistance were 27.6% (72\/261) and 36.4% (95\/261), respectively. The detection rates of MDR\u2010TB and pre\u2010extensively drug\u2010resistant TB (pre\u2010XDR\u2010TB) were 73.2% (191\/261) and 36.4% (95\/261), respectively, and the trends were significant (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup> trend\u2009=\u20099.995, <jats:italic>p<\/jats:italic>\u2009=\u20090.002; <jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup> trend\u2009=\u200912.744, <jats:italic>p<\/jats:italic>\u2009=\u20090.026). Among the 261 RR\u2010TB strains, 14.9% (24\/261) were sensitive to LFX but resistant to MFX. Among the four patients with LFX\u2010resistant TB who received LFX treatment failed in three patients(Fisher's exact test, <jats:italic>p<\/jats:italic>\u2009=\u20090.009). The common mutation sites were 94\u00a0and 90 in gyrA. A novel mutation Ala90Ser was discovered.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>FQs resistance trends in RR\u2010TB patients in Beijing are striking. Strains showed incomplete cross\u2010resistance to LFX and MFX. Testing for FQs resistance and developing a reasonable treatment plan are recommended. Attention should be given to the changing trends in MDR\u2010TB and pre\u2010XDR\u2010TB.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ame2.12505","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T03:49:36Z","timestamp":1738813776000},"page":"906-915","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Study of fluoroquinolones\u00a0resistance in rifampicin\u2010resistant tuberculosis patients in Beijing: Characteristics, trends, and treatment outcomes"],"prefix":"10.1002","volume":"8","author":[{"given":"Wang","family":"Nenhan","sequence":"first","affiliation":[{"name":"Beijing Center for Disease Prevention and Control  Beijing People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Lili","sequence":"additional","affiliation":[{"name":"Beijing Center for Disease Prevention and Control  Beijing People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Yanfeng","sequence":"additional","affiliation":[{"name":"Beijing Center for Disease Prevention and Control  Beijing People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Shuangshuang","sequence":"additional","affiliation":[{"name":"Beijing Center for Disease Prevention and Control  Beijing People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"LiYing","sequence":"additional","affiliation":[{"name":"Beijing Center for Disease Prevention and Control  Beijing People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Qiao","sequence":"additional","affiliation":[{"name":"Institute of Pathogen Biology Chinese Academy of Medical Sciences  Beijing People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chuanyou","sequence":"additional","affiliation":[{"name":"Beijing Center for Disease Prevention and Control  Beijing People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4021-6215","authenticated-orcid":false,"given":"Dai","family":"Xiaowei","sequence":"additional","affiliation":[{"name":"Beijing Center for Disease Prevention and Control  Beijing People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"Global Tuberculosis Report 2023","author":"World Health Organization","year":"2023"},{"key":"e_1_2_10_3_1","unstructured":"WHO.WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment\u2010Drug\u2010Resistant Tuberculosis Treatment (2020)."},{"key":"e_1_2_10_4_1","volume-title":"Technical Report on Critical Concentrations for Drug Susceptibility Testing of Medicines Used in the Treatment of Drug\u2010Resistant Tuberculosis","year":"2018"},{"key":"e_1_2_10_5_1","volume-title":"Optimized Broth Microdilution Plate Methodology for Drug Susceptibility Testing of Mycobacterium Tuberculosis Complex","author":"World Health Organization","year":"2022"},{"issue":"3","key":"e_1_2_10_6_1","first-page":"94","article-title":"Research on the influence of coordinated development strategy of Beijing\u2010Tianjin\u2010Hebei on Beijing's population scale control","volume":"42","author":"Guoping L","year":"2021","journal-title":"J Hebei Univ Econ Bus"},{"key":"e_1_2_10_7_1","unstructured":"Technical Manual for Drug Susceptibility Testing of Medicines Used in the Treatment of Tuberculosis. Licence: CC BY\u2010NC\u2010SA 3.0 IGO."},{"key":"e_1_2_10_8_1","volume-title":"CLSI supplement M24S","author":"CLSI","year":"2023"},{"key":"e_1_2_10_9_1","volume-title":"Meeting Report of the WHO Expert Consultation on the Definition of Extensively Drug\u2010Resistant Tuberculosis","author":"World Health Organization","year":"2021"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1000-6621.2019.10.001"},{"key":"e_1_2_10_11_1","first-page":"183","volume-title":"Technical Guidelines for Tuberculosis Prevention and Control in China","author":"Zhao YL","year":"2021"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2010.11.008"},{"issue":"10","key":"e_1_2_10_13_1","first-page":"727","article-title":"Re evaluation of the application of fluoroquinolones in drug\u2010resistant tuberculosis","volume":"37","author":"Shenjie T","year":"2014","journal-title":"Chinese J Tuber Respir Dis"},{"key":"e_1_2_10_14_1","volume-title":"Global Tuberculosis Report 2021","author":"World Health Organization","year":"2021"},{"key":"e_1_2_10_15_1","volume-title":"Report on the Management and Resistance Status of Antibiotics in China (2018)","author":"National Health Commission of the People's Republic of China","year":"2019"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-020-00709-6"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108789"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn311365-20210406-00117"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2017.08.014"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165222"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30190-6"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1019198"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06024-8"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.11.03"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1000-6621.2014.06.009"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.00409-21"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.01.021"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-023-04700-y"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01228-13"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00036-08"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S178831"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2302837"},{"issue":"9","key":"e_1_2_10_33_1","first-page":"706","article-title":"Analysis of the relationship between gyrA mutations and fluoroquinolone levels in Mycobacterium tuberculosis isolates from China","volume":"38","author":"Zhang ZG","year":"2016","journal-title":"Chinese J Antitubercul"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01354-2017"},{"key":"e_1_2_10_35_1","volume-title":"Catalogue of Mutations in Mycobacterium tuberculosis Complex and their Association with Drug Resistance","author":"World Health Organization","year":"2021"},{"key":"e_1_2_10_36_1","volume-title":"Catalogue of Mutations in Mycobacterium tuberculosis Complex and their Association with Drug Resistance","author":"World Health Organization","year":"2023"}],"container-title":["Animal Models and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ame2.12505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T10:10:13Z","timestamp":1748340613000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ame2.12505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1002\/ame2.12505"],"URL":"https:\/\/doi.org\/10.1002\/ame2.12505","archive":["Portico"],"relation":{},"ISSN":["2576-2095","2576-2095"],"issn-type":[{"value":"2576-2095","type":"print"},{"value":"2576-2095","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"2024-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}